The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Mark Jit*, Joke Bilcke, Marie Josée J. Mangen, Heini Salo, Hugues Melliez, William Edmunds, Yazdanpanah Yazdan, Philippe Beutels

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

82 Citations (Scopus)

Abstract

Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix®, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of €30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix® (excluding administration costs) to be cost effective was €41 in Belgium, €28 in England and Wales, €51 in Finland, €36 in France and €46 in the Netherlands.

Original languageEnglish
Pages (from-to)6121-6128
Number of pages8
JournalVaccine
Volume27
Issue number44
DOIs
Publication statusPublished - 19 Oct 2009

Bibliographical note

Funding Information:
We thank Thierry van Effelterre (GSK Biologicals Belgium) for sharing results from his dynamic model of rotavirus vaccination in Belgium. This study formed part of POLYMOD, a European Commission project funded within the Sixth Framework Programme, Contract number: SSP22-CT-2004–502084. MJ was funded by the Policy Research Programme in the Department of Health, England (grant number 039/0031). WJE's partner works for GlaxoSmithKline. YY has received travel grants and honoraria for presentations at workshops and for consultancy from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec.

Keywords

  • Cost-effectiveness
  • Rotavirus
  • Vaccination

Fingerprint

Dive into the research topics of 'The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe'. Together they form a unique fingerprint.

Cite this